Innovators and start-ups in healthcare and biotech are experts in their innovation’s scientific and technical domain but often struggle with navigating the complex world of the healthcare industry.
If you want to objectively show the advantages and competitiveness of your innovation to potential investors, future users, (reimbursement) payers or even the media, you can greatly benefit from Mercury Pharmaceuticals’s Health Innovation Assessment solution.
By making use of robust methods to collect and analyse data, Health Innovation Assessment (HIA) aims to comprehensively assess the added value of (bio-)medical and healthcare innovations. HIA takes into account true multi-stakeholder perspectives on value assessment and the realm of marketplace decision making.
Clinical trials are very important as it allow us to evaluate the effectiveness of new drugs, new devices, preventative strategies or treatment strategies. It also enables us to discover better ways for patients' care.
- Learn more
Our mission remains constant as we endeavor to deliver novel medicines to patients with cancer, treating solid tumors with high unmet medical needs in well-defined patient populations that are currently not well supported.
- Learn more
Whether you're looking to manufacture toxicology batches or cGMP material for clinical trials, we can help you expedite molecules to clinic with full transparency.
- Learn more
24
Jan 2026
When firefighters respond to an emergency, the gear they wear to protect themselves can also create challenges that could jeopardize their performance and safety.
24
Jan 2026
A multidisciplinary USC research team has identified new compounds that may target a key driver of brain inflammation linked to Alzheimer's disease. Their research just published in the Nature publication npj Drug Discovery.
24
Jan 2026
A landmark study led by researchers with the Department of Veterans Affairs has uncovered new genetic insights into schizophrenia by analyzing data from ancestrally diverse populations, including African Americans, through the Million Veteran Program (MVP) and Cooperative Studies Program (CSP).
24
Jan 2026
Two recent studies from the University of California, Riverside, published in the same issue of Gut Microbes highlight the role of a gene called PTPN2 in protecting the gut from harmful bacteria linked to inflammatory bowel disease (IBD).